Cart
sales@molnova.com
LRE1
CAS No. 1252362-53-0
LRE1 ( —— )
Catalog No. M26744 CAS No. 1252362-53-0
LRE1 is a specific and allosteric soluble adenylyl cyclase inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 50 | Get Quote |
|
| 10MG | 87 | Get Quote |
|
| 25MG | 170 | Get Quote |
|
| 50MG | 320 | Get Quote |
|
| 100MG | 476 | Get Quote |
|
| 500MG | 1062 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLRE1
-
NoteResearch use only, not for human use.
-
Brief DescriptionLRE1 is a specific and allosteric soluble adenylyl cyclase inhibitor.
-
DescriptionLRE1 is a specific and allosteric soluble adenylyl cyclase inhibitor.(In Vitro):LRE1 prevents sAC-dependent processes in cellular and physiological systems and facilitates exploration of the therapeutic potential of sAC inhibition. LRE1 binds to the bicarbonate activator binding site and suppresses soluble adenylyl cyclase (sAC) via a unique allosteric mechanism.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorS1PR1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1252362-53-0
-
Formula Weight280.8
-
Molecular FormulaC12H13ClN4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESNc1nc(Cl)cc(n1)N(Cc1cccs1)C1CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bigaud M, et al. Pathophysiological Consequences of a Break in S1P1-Dependent Homeostasis of Vascular Permeability Revealed by S1P1 Competitive Antagonism. PLoS One. 2016 Dec 22;11(12):e0168252.
molnova catalog
related products
-
ST-034307
ST-034307 (ST 034307, ST034307) is a potent, selective adenylyl cyclase 1 (AC1) with IC50 of 2.3 uM.
-
NB 001
A potent, relatively selective and orally active adenylyl cyclase 1 (AC1) inhibitor with IC50 of 10 uM (cAMP production inhibition).
-
LRE1
A novel potent, specific and allosteric soluble adenylyl cyclase (sAC) inhibitor with IC50 of 3.3 uM in RF-MSS assays.
